Pareptide
Source Pareptide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Pareptide is a synthetic analogue of the neuropeptide melanotropin‑inhibiting factor (MIF‑1). It is employed primarily as a research tool to study peptide metabolism, dopaminergic receptor interactions, and the development of tolerance to antipsychotic‑induced catalepsy in rodents. The compound has been characterized in biochemical assays for its stability in brain tissue and quantified in biological fluids using high‑performance liquid chromatography. Its short peptide sequence lacks a C‑terminal amidation, yet retains activity comparable to MIF‑1 in experimental models.
Mechanism of Action
Pareptide appears to modulate dopaminergic signalling. In vitro, nanomolar concentrations of pareptide enhance the binding of radiolabelled apomorphine to rat striatal receptors, indicating a facilitative effect on dopamine‑type receptors. In vivo, sub‑chronic administration prevents the emergence of tolerance to haloperidol‑induced catalepsy in mice, a behavioural outcome linked to dopaminergic pathways. Biochemically, the peptide is hydrolysed in brain tissue by leucine aminopeptidase and related enzymes, initiating degradation from the N‑terminus, which may influence its duration of action.
What the Research Shows
The literature on pareptide consists of five peer‑reviewed reports. Early work used pareptide as an internal standard to quantify degradation of the endogenous peptide MIF in rat brain, identifying leucine aminopeptidase and related enzymes as responsible for N‑terminal hydrolysis, with regional activity differences across striatum, medulla and other areas. Two chromatographic studies described sensitive HPLC‑fluorometric methods for detecting pareptide in human urine and plasma, establishing limits of detection down to nanomole levels. In mouse behavioural experiments, single and repeated sub‑cutaneous doses (0.25 mg kg⁻¹) of pareptide did not alter the acute cataleptic response to haloperidol but blocked the development of tolerance after chronic haloperidol pretreatment. A later investigation compared pareptide with related tripeptides, showing that all three increased ³H‑apomorphine binding to rat striatal membranes in a bell‑shaped dose‑response, confirming that C‑terminal amidation is not essential for activity. Collectively, these studies portray pareptide as a biologically active MIF‑1 analogue useful for probing peptide metabolism, dopaminergic receptor interactions, and drug‑tolerance mechanisms in rodent models.
Reported Benefits
In experimental rodents, pareptide has demonstrated the ability to prevent the onset of tolerance to haloperidol‑induced catalepsy, suggesting a modulatory effect on dopaminergic pathways involved in antipsychotic tolerance. In vitro assays show that nanomolar concentrations enhance apomorphine binding to striatal receptors, indicating potential utility as a probe of dopamine receptor function. Additionally, the peptide serves as a reliable internal standard for high‑performance liquid chromatography methods to measure MIF‑related peptides in biological fluids, facilitating biochemical investigations.
Limitations of the Evidence
The evidence for pareptide is confined to pre‑clinical studies; no human clinical trials or safety evaluations have been reported. Reported effects are limited to rodent behavioural models and in vitro rat brain membrane assays, which may not translate to human physiology. Moreover, dosing information is sparse, and pharmacokinetic parameters such as half‑life, distribution, or metabolism in vivo remain undefined. Furthermore, the peptide’s activity appears modest and dose‑dependent, with bell‑shaped responses, indicating a narrow therapeutic window in experimental settings.
Safety Considerations
No adverse events were described in the animal studies that employed sub‑cutaneous doses of 0.25 mg kg⁻¹ for up to 3½ days, and the authors did not report toxicity. Human data are absent; the analytical studies measured pareptide in plasma and urine but did not assess safety. Consequently, potential risks, including immunogenicity, off‑target effects, or metabolic by‑products, remain unknown. Researchers should treat pareptide as an experimental reagent and observe standard laboratory safety practices when handling synthetic peptides.
How It Is Administered
In the published rodent experiments, pareptide was administered by sub‑cutaneous injection, typically at 0.25 mg kg⁻¹ twice daily for several days. Analytical protocols have quantified the peptide in human plasma and urine using high‑performance liquid chromatography coupled with fluorometric detection after derivatization, but no therapeutic formulation has been described.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleLowHui KS, et al.1980-01-01T00:00:00.000000Z
- Journal ArticleLowHui KS, et al.1981-01-01T00:00:00.000000Z
- Pro-Leu-Gly-NH2 and pareptide inhibit development of tolerance to haloperidol catalepsy in the mouseJournal ArticleLowMycroft FJ, Wei ET1984-01-01T00:00:00.000000Z
- Journal ArticleLowMycroft FJ, Bhargava HN, Wei ET1987-01-01T00:00:00.000000Z
- Journal ArticleLowKrol GJ, et al.1979-01-01T00:00:00.000000Z
Frequently Asked Questions
What is pareptide?
Pareptide is a synthetic analogue of the neuropeptide melanotropin‑inhibiting factor (MIF‑1). It is used in laboratory research to explore peptide metabolism, dopaminergic receptor activity, and drug‑tolerance mechanisms, primarily in rodent and in vitro systems.
How is pareptide administered in experimental studies?
Published animal work employed sub‑cutaneous injections, usually at a dose of 0.25 mg per kilogram of body weight given twice daily for several days. In analytical studies, the peptide is measured in plasma or urine after derivatization for HPLC‑fluorometric detection.
Has pareptide been tested in humans for therapeutic use?
No human clinical trials or therapeutic evaluations have been reported. The only human‑related work involves analytical methods to detect the peptide in biological fluids; safety and efficacy in patients remain unstudied.
What effects does pareptide have in animal models?
In mice, repeated pareptide treatment prevented the development of tolerance to haloperidol‑induced catalepsy, suggesting an influence on dopaminergic pathways. In vitro, it enhances apomorphine binding to rat striatal receptors at nanomolar concentrations.